Buy & Sell YieldMax NVDA Option Income Strategy ETF (NVDY) – YieldMax NVDA Option Income Strategy ETF Price Today
Aura AI Summary
Key Stats
- -Market Cap
- Income / Options OverlaySector
- -14.5%3M Drawdown
- -Enterprise Value
- -Dividend Yield
- 11% Buy | 89% SellTrading Activity
- 18 daysTypical Hold Time
Over the past 52 weeks, YieldMax NVDA Option Income Strategy ETF has traded between a low of $12.38 and a high of $17.96, highlighting its annual price range. Over the past three months, YieldMax NVDA Option Income Strategy ETF has recorded a drawdown of -14.5%, reflecting recent price volatility. On average, investors hold YieldMax NVDA Option Income Strategy ETF for approximately 18 days, indicating typical investor behavior on the platform.
About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Most Recent News
Over 100 drugs in clinical trials aim to transform age-related macular degeneration treatment by 2026
DelveInsight's 2026 report reveals more than 100 drugs in development for age-related macular degeneration (AMD), involving over 90 companies globally. These therapies include novel mechanisms like gene therapy, mitochondrial stabilization, and VEGF ...

Cell and gene therapy CDMO market set to grow at 24% CAGR, reaching $57.1B by 2034.
The cell and gene therapy contract development and manufacturing organization (CDMO) market is projected to grow at a compound annual growth rate (CAGR) of approximately 24% from 2026 to 2034, reaching a market size of $57.1 billion by 2034. Growth i...

Polymeric biomaterials market to hit $267B by 2034, driven by regenerative medicine and healthcare growth.
The global polymeric biomaterials market, valued at $69.55 billion in 2024, is projected to grow at a CAGR of 15.86% to reach $267.25 billion by 2034. Growth is fueled by increasing demand in regenerative medicine, orthopedics, and wound care, with A...
